TLS Advisors’s Ovid Therapeutics OVID Stock Holding History

TLS Advisors’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41K	Buy	18,858 +5,258	+39%	+$9.4K	0.1%	16
2025 Q4	$374K	Sell	13,600 -5,258	-28%	-$8.1K	0.98%	12
2025 Q3	$26K	Sell	18,858 -662,109	-97%	-$574K	0.08%	18
2025 Q2	$225K	Hold	680,967	–	–	0.7%	12
2025 Q1	$213K	Hold	680,967	–	–	0.48%	15
2024 Q4	$636K	Sell	680,967 -90,564	-12%	-$101K	1.45%	11
2024 Q3	$910K	Sell	771,531 -353,765	-31%	-$370K	1.92%	11
2024 Q2	$866K	Sell	1,125,296 -194,383	-15%	-$541K	2.17%	11
2024 Q1	$4.03M	Hold	1,319,679	–	–	9.37%	6
2023 Q4	$4.25M	Hold	1,319,679	–	–	14.1%	3
2023 Q3	$5.07M	Hold	1,319,679	–	–	20.5%	2
2023 Q2	$4.33M	Sell	1,319,679 -60,667	-4%	-$206K	18.57%	2
2023 Q1	$3.52M	Sell	1,380,346 -110,188	-7%	-$261K	18.08%	2
2022 Q4	$2.77M	Buy	+1,490,534	New	+$2.54M	13.66%	2

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

TLS Advisors's OVID Position: Q1 2026 in Review

TLS Advisors increased its Ovid Therapeutics (OVID) stake by 39% in Q1 2026, buying an estimated $9.4K and bringing the position to 18,858 shares worth $41K. The position accounts for 0.1% of the portfolio, ranked #16.

TLS Advisors first reported a position in OVID in Q4 2022 and has held it in 14 quarters since. The position peaked at $5.07M in Q3 2023. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

TLS Advisors held 18,858 shares of Ovid Therapeutics worth $41K as of Q1 2026.
TLS Advisors bought 5,258 Ovid Therapeutics shares in Q1 2026, an estimated $9.4K.
Ovid Therapeutics made up 0.1% of TLS Advisors's portfolio in Q1 2026, its #16 holding.
TLS Advisors first reported a position in Ovid Therapeutics in Q4 2022 and has held it in 14 quarters since.
TLS Advisors's Ovid Therapeutics position peaked at $5.07M in Q3 2023.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on TLS Advisors's 13F filing for Q1 2026, filed 13 May 2026.